Table 1. Summary of Study Population and Main Results.
| Characteristic | Participants, No. (%) | |
|---|---|---|
| SARS-CoV-2 infection (n = 62 447) | SARS-CoV-2 vaccine (n = 3 006 662) | |
| Sex | ||
| Male | 58 989 (94.5) | 1 626 623 (54.1) |
| Female | 3458 (5.5) | 1 380 039 (45.9) |
| Age, median (range), y | 34 (0-102) | 50 (12-121) |
| Subtype of vaccines received | ||
| BNT162b2 | NA | 2 283 221 (75.9) |
| mRNA-1273 | NA | 723 441 (24.1) |
| Total duration of exposure, person-years | 7205 | 346 923 |
| No. of CVT hospitalizations | 6 | 9 |
| Age, median (range), y | 34 (27-40) | 60 (46-76) |
| Male sex | 6 (100) | 7 (77.8) |
| Female sex | 0 | 2 (22.2) |
| Annualized crude incidence rate of CVT hospitalization, per 100 000 person-years (95% CI) | 83.3 (30.6-181.2) | 2.59 (1.19-4.92) |
| Crude incidence rate ratio of CVT hospitalization (95% CI) | 32.1 (9.4-101.0) | [Reference] |
| P value | <.001 | NA |
Abbreviations: mRNA, messenger RNA; NA, not applicable.